Sign in

NCT07201077Completed

ArticuGrasp Trial: New Flexible Tool vs Standard Grasper for Lung Cancer Node Removal in Keyhole Chest Surgery

Overcoming Instrumentation Challenges in Real-World Uniportal Video-Assisted Thoracoscopic Surgery: A Prospective, Randomized, Controlled Trial Evaluating the SurgeoFlex Grasp Versus the Traditional Endograsper for Systemic Lymph Node Dissection in Patients With Early-Stage Non-Small Cell Lung Cancer

Source: ClinicalTrials.gov · Last updated 1 Oct 2025

Brief summary (registry, in English)

This study is testing whether a new, flexible surgical tool-the SurgeoFlex Grasp-makes keyhole chest operations for early-stage lung cancer easier, faster, and safer than the standard rigid tool used today. What is the problem? In keyhole (uniportal) chest surgery, formally known as single-port video-assisted thoracoscopic surgery (VATS), surgeons reach the lung through one small incision between the ribs. Because the operating space is tight, the usual stiff instruments can bump into each other and into surrounding tissues. This difficulty can prolong lymph-node removal and increase the risk of complications. What is being tested? The trial compares two handheld tools: SurgeoFlex Grasp (intervention): a slim, bendable grasper that can be steered around corners. Traditional EndoGrasper (control): a straight, rigid grasper currently used as the standard. Who is taking part? Approximately 100 adults with early-stage non-small-cell lung cancer (NSCLC) (tumours 3 cm or smaller) who are scheduled for keyhole surgery at The First Affiliated Hospital of Guangzhou Medical University. What will happen? Participants are allocated by randomisation into one of two groups: SurgeoFlex group-surgeons use the new flexible tool. Control group-surgeons use the standard rigid tool. All other aspects of the operation, anaesthesia, and post-operative care remain identical for both groups. What is measured? Lymphadenectomy time (duration required to remove the specified lymph nodes). Number of lymph nodes successfully removed. Frequency of surgical-instrument collisions or interference (instrument-clash events). Surgeon workload during the operation (assessed with the National Aeronautics and Space Administration Task Load Index \[NASA-TLX\]). Skin-incision length, pain scores (Visual Analogue Scale \[VAS\]), recovery time, infection rates, and overall cost. Quality-of-life scores one month after surgery (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 \[EORTC QLQ-C30\] and its lung-cancer module \[EORTC QLQ-LC13\]). What is expected? The investigators expect the SurgeoFlex Grasp to shorten operative time, reduce instrument interference, lower surgeon stress, and accelerate recovery without increasing cost. How will this help patients? If the new tool performs as anticipated, future patients undergoing keyhole lung-cancer surgery may experience shorter operations, smaller scars, less pain, and lower infection risk while still obtaining complete cancer-related lymph-node removal. Where is the study taking place? The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. Contact for more information: Clinical Research Management Committee 151 Yanjiang Road, Yuexiu District, Guangzhou 510120, China Email:

Status (registry)
Completed
Study type
Interventional
Enrollment
100 (actual)
First submitted
15 Aug 2025
Start date
1 Jan 2025
Primary completion date
31 Mar 2025
Lead sponsor
Jianxing He
Diseases
Lung cancer
NCT number
NCT07201077

What you commit to

  • Study type: Interventional
  • Participants enrolled: 100
  • From 1 Jan 2025 to the primary completion date, 31 Mar 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Previous ipsilateral thoracic surgery or prior neoadjuvant chemotherapy, radiotherapy, targeted therapy, or immunotherapy

Other illness

  • Small-cell lung cancer or mixed-type lung cancer

Lab values

  • Severe cardiopulmonary dysfunction (FEV₁ \<50 % predicted or LVEF \<40 %)

Other

  • Tumor invasion of main bronchus, chest wall, diaphragm, or major mediastinal vessels
  • Pregnant or breastfeeding women
  • Participation in another interventional clinical trial

Who the study is looking for

  • Age 18-70 years, any sex
  • BMI 18.5-30 kg/m²
  • Newly diagnosed non-small-cell lung cancer with pre-operative clinical stage cT1-2N0-1M0
  • Scheduled to undergo single-port video-assisted thoracoscopic lobectomy with systematic lymph-node dissection
  • Major organ function sufficient for surgery
  • Written informed consent provided

Criteria the registry did not label

  • Eligibility Criteria

Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
The First Affiliated Hospital of Guangzhou Medical University
Coordinator of this site? Confirm its status
GuangzhouChinaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.